PL1697507T3 - Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS - Google Patents

Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS

Info

Publication number
PL1697507T3
PL1697507T3 PL04805624T PL04805624T PL1697507T3 PL 1697507 T3 PL1697507 T3 PL 1697507T3 PL 04805624 T PL04805624 T PL 04805624T PL 04805624 T PL04805624 T PL 04805624T PL 1697507 T3 PL1697507 T3 PL 1697507T3
Authority
PL
Poland
Prior art keywords
fragments
isolated
genome
positions
sars
Prior art date
Application number
PL04805624T
Other languages
English (en)
Inventor
Der Werf Sylvie Van
Nicolas Escriou
Bernadette Crescenzo-Chaigne
Jean-Claude Manuguerra
Frederik Kunst
Benoît Callendret
Jean-Michel Betton
Valérie Lorin
Sylvie Gerbaud
Ana Maria Burguiere
Saliha Azebi
Pierre Charneau
Frédéric Tangy
Chantal Combredet
Jean-François Delagneau
Monique Martin
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Univ Paris Vii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0314152A external-priority patent/FR2862981B1/fr
Priority claimed from FR0314151A external-priority patent/FR2862974B1/fr
Application filed by Pasteur Institut, Centre Nat Rech Scient, Univ Paris Vii filed Critical Pasteur Institut
Publication of PL1697507T3 publication Critical patent/PL1697507T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
PL04805624T 2003-12-02 2004-12-02 Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS PL1697507T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0314152A FR2862981B1 (fr) 2003-12-02 2003-12-02 Nouvelle souche de coronavirus associe au sras et ses applications
FR0314151A FR2862974B1 (fr) 2003-12-02 2003-12-02 Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras
EP04805624A EP1697507B1 (fr) 2003-12-02 2004-12-02 Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras
PCT/FR2004/003105 WO2005056781A1 (fr) 2003-12-02 2004-12-02 Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras.

Publications (1)

Publication Number Publication Date
PL1697507T3 true PL1697507T3 (pl) 2013-03-29

Family

ID=34680402

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04805624T PL1697507T3 (pl) 2003-12-02 2004-12-02 Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS

Country Status (9)

Country Link
US (4) US7736850B2 (pl)
EP (4) EP2275534A1 (pl)
JP (3) JP5090741B2 (pl)
AT (1) ATE476498T1 (pl)
CA (2) CA2549594A1 (pl)
DE (1) DE602004028506D1 (pl)
ES (1) ES2396127T3 (pl)
PL (1) PL1697507T3 (pl)
WO (2) WO2005056584A2 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1882741B1 (en) * 2006-07-25 2010-06-30 Institut Pasteur Recombinant Mycobacterium strain expressing a mycobacterial FAP protein under the control of a promoter active under hypoxia and its application for cancer therapy
EP1939214B1 (en) 2006-12-22 2013-07-10 Institut Pasteur Cells and methodology to generate non-segmented negative-strand RNA viruses
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
AU2012242847B2 (en) 2011-04-15 2017-01-19 The Johns Hopkins University Safe sequencing system
ES2701742T3 (es) 2012-10-29 2019-02-25 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
GB201318804D0 (en) * 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
AU2015289386A1 (en) 2014-07-18 2017-03-09 Celltheon Corporation Methods and compositions for expression of polypeptides in a cell
US10072309B1 (en) * 2015-05-08 2018-09-11 Dougbeh-Chris Nyan Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and protozoan nucleic acids
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
CN120400338A (zh) 2017-08-07 2025-08-01 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
CA3167611A1 (en) 2020-02-13 2021-08-19 Etienne Simon-Loriere Nucleic acid vaccine against the sars-cov-2 coronavirus
IL295297A (en) 2020-02-14 2022-10-01 Univ Johns Hopkins Methods and materials for assessing nucleic acids
EP4103232A4 (en) * 2020-02-14 2025-03-26 Epivax, Inc. Regulatory t cell epitopes and detolerized sars-cov-2 antigens
GB2594683A (en) * 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine
CN111334608B (zh) * 2020-02-19 2022-04-12 北京亿森宝生物科技有限公司 用于检测新型冠状病毒2019-nCoV的双重荧光冻干微芯片、试剂盒及方法
CN113186226B (zh) * 2020-02-25 2022-08-05 广州复能基因有限公司 Rna病毒核酸检测参照标准品及其用途
US12195811B2 (en) 2020-03-09 2025-01-14 Roche Molecular Systems, Inc. Compositions and methods for detecting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A and Influenza B
EP4119575A4 (en) * 2020-03-10 2024-07-03 Denka Company Limited Epitope of antibody against structural protein of sars-cov-2, antibody reacting with epitope, method for detecting sars-cov-2 using antibody, detection kit for sars-cov-2 containing antibody, method for detecting anti-sars-cov-2 antibody containing polypeptide of epitope, detection kit for anti-sars-cov-2 antibody containing polypeptide of epitope, vaccine for sars-cov-2 containing polypeptide of epitope, and therapeutic agent for sars-cov-2 infection containing antibody
CN113621034A (zh) * 2020-03-17 2021-11-09 杭州康柏睿格医药科技有限公司 具有免疫反应性的新冠状病毒b-细胞抗原
WO2021188966A1 (en) * 2020-03-19 2021-09-23 Massachusetts Institute Of Technology Sars-cov-2 spike protein binding peptides
WO2021188906A1 (en) * 2020-03-19 2021-09-23 Nature's Toolbox, Inc. Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same
US20230149534A1 (en) * 2020-03-20 2023-05-18 BioVaxys Inc. Haptenized coronavirus spike proteins
WO2021189032A1 (en) * 2020-03-20 2021-09-23 Yu Ruey J Coronavirus: early detection and treatment
WO2021188837A1 (en) * 2020-03-20 2021-09-23 The Johns Hopkins University Prophylaxis and treatment of pathogenic coronavirus infections
MX2022011892A (es) 2020-03-26 2022-10-18 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
WO2021195485A1 (en) * 2020-03-27 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US11149320B1 (en) 2020-03-31 2021-10-19 Diasorin S.P.A. Assays for the detection of SARS-CoV-2
IT202000006754A1 (it) 2020-03-31 2021-10-01 Diasorin S P A Saggi per la rivelazione di SARS-CoV-2
US12326451B2 (en) 2020-04-01 2025-06-10 Institut Pasteur Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
US10948490B1 (en) * 2020-04-01 2021-03-16 Institut Pasteur Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
WO2021205083A2 (fr) 2020-04-11 2021-10-14 Finindsutria Srl Composition pour la prévention ou le traitement du covid-19
CN113521269A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
WO2021222316A2 (en) 2020-04-27 2021-11-04 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
WO2021220137A2 (en) * 2020-04-27 2021-11-04 Sapir Pharmaceuticals Inc. Pannexin-1 inhibitors for the treatment of sars-cov-2 infected covid-19 patients with or without an associated acute respiratory syndrome
WO2021236869A2 (en) * 2020-05-20 2021-11-25 The Johns Hopkins University Virus detection methods
WO2021248017A2 (en) * 2020-06-05 2021-12-09 Vaxart, Inc. Chimeric adenoviral vectors
CN111830120B (zh) * 2020-06-10 2023-06-09 北京东西分析仪器有限公司 应用质谱系统鉴定新冠病毒的试剂盒及其使用方法
WO2021252901A2 (en) * 2020-06-12 2021-12-16 The Penn State Research Foundation Pandemic-preparedness cocktail to fight coronavirus outbreaks
CN111996288A (zh) * 2020-07-27 2020-11-27 深圳市真迈生物科技有限公司 检测冠状病毒的组合物、试剂盒和方法
CN116568710A (zh) * 2020-10-28 2023-08-08 奥索临床诊断有限公司 用于检测SARS-CoV-2抗原的高通量免疫测定和方法
CN114716541B (zh) * 2021-01-05 2023-07-21 中国科学院分子细胞科学卓越创新中心 抗冠状病毒的全人广谱中和抗体76e1及其应用
WO2022150740A1 (en) * 2021-01-11 2022-07-14 Board Of Regents, The University Of Texas System Cross-reactive antibodies recognizing the coronavirus spike s2 domain
WO2023287324A1 (en) * 2021-07-16 2023-01-19 Joint Stock Company "Biocad" Influenza virus-based isolated recombinant virus
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114702555B (zh) * 2022-03-09 2023-01-03 中国计量科学研究院 新型冠状病毒核衣壳蛋白n蛋白的制备和定值方法
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69832970T2 (de) 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
US20020064801A1 (en) * 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
JP4463481B2 (ja) * 2001-05-17 2010-05-19 ウニフェルシテイト ユトレヒト 機能的に欠失したゲノムを含むコロナウイルス様の粒子
US7220852B1 (en) * 2003-04-25 2007-05-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Coronavirus isolated from humans
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US20050100883A1 (en) * 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
WO2009149300A1 (en) 2008-06-04 2009-12-10 Sixpoint Materials High-pressure vessel for growing group iii nitride crystals and method of growing group iii nitride crystals using high-pressure vessel and group iii nitride crystal
BRPI0823394A2 (pt) 2008-12-23 2015-06-16 Calera Corp Sistema e método eletroquímico de hidróxido de baixa energia

Also Published As

Publication number Publication date
CA2549594A1 (fr) 2005-06-23
JP5054384B2 (ja) 2012-10-24
JP5090741B2 (ja) 2012-12-05
WO2005056584A3 (fr) 2005-08-25
JP2007512826A (ja) 2007-05-24
EP1694829A2 (fr) 2006-08-30
ATE476498T1 (de) 2010-08-15
EP2275534A1 (fr) 2011-01-19
EP1697507B1 (fr) 2012-09-19
US20070275002A1 (en) 2007-11-29
US20070128224A1 (en) 2007-06-07
US7736850B2 (en) 2010-06-15
US8343718B2 (en) 2013-01-01
EP2361974A1 (fr) 2011-08-31
EP1694829B1 (fr) 2010-08-04
DE602004028506D1 (de) 2010-09-16
WO2005056781A1 (fr) 2005-06-23
JP2007536907A (ja) 2007-12-20
US20120082693A1 (en) 2012-04-05
EP1697507A1 (fr) 2006-09-06
CA2549188A1 (fr) 2005-06-23
US20110065089A1 (en) 2011-03-17
WO2005056584A2 (fr) 2005-06-23
JP2012165750A (ja) 2012-09-06
ES2396127T3 (es) 2013-02-19

Similar Documents

Publication Publication Date Title
ATE476498T1 (de) Neuer mit sars verbunden coronavirus stamm und seine verwendungen
Chen et al. Molecular characterization and phylogenetic analysis of membrane protein genes of porcine epidemic diarrhea virus isolates in China
CA2328989A1 (en) Serpentine transmembrane antigens expressed in human cancers and uses thereof
Goszczynski et al. Identification of divergent variants of Grapevine virus A
DE60328880D1 (de) Oligonukleotide von für die oberflächenkomponente des ptlv-hüllproteins codierenden sequenzen und verwendungen davon
Piggott et al. Gene cloning of a thaumatin-like (PR-5) protein of western white pine (Pinus monticola D. Don) and expression studies of members of the PR-5 group
CA2362527A1 (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
Vidgren et al. Nucleotide sequence of the genes coding for the membrane glycoproteins E1 and E2 of rubella virus
CN111676320A (zh) 一种猪流行性腹泻病毒s基因全序列扩增方法及其应用
WO1998006841A3 (en) Two human nsp-like proteins
Lovato et al. The full-length cDNA of anticoagulant protein infestin revealed a novel releasable Kazal domain, a neutrophil elastase inhibitor lacking anticoagulant activity
Libby et al. Human rhinovirus 3C protease: cloning and expression of an active form in Escherichia coli
EP1284297A3 (en) Identification and use of molecules implicated in pain
EP1279744A3 (en) Identification and use of molecules implicated in pain
CN108976298B (zh) 一种来源于凡纳滨对虾血蓝蛋白的抗WSSV肽LvHcS52及其应用
JP2005535287A5 (pl)
CA2232237A1 (en) Reagents and methods useful for detecting diseases of the breast
Pfrepper et al. Expression and molecular characterization of an enzymatically active recombinant human spumaretrovirus protease
WO1991014779A1 (fr) Diagnostic du virus de l'hepatite
AU2004225718B2 (en) Inhibitor proteins of a protease and use thereof
Holtet et al. Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative
JP2002518016A5 (pl)
CN107523572A (zh) 菜蛾盘绒茧蜂畸形细胞丝氨酸蛋白酶抑制剂CvT‑SPI基因及应用
CN102978211B (zh) 一种目的蛋白制备方法及其用途
US11656232B2 (en) Agents and methods for diagnosing fish allergy